TAP
GILD icon

Tounjian Advisory Partners’s Gilead Sciences GILD Stock Holding History

Tounjian Advisory Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,724
Closed -$417K – 189
2025
Q2 		$417K Sell
3,724
-58
-2% -$6.17K 0.08% 199
2025
Q1 		$424K Buy
+3,782
New +$390K 0.08% 199

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tounjian Advisory Partners's GILD Position: Q3 2025 in Review

Tounjian Advisory Partners sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 3,724 shares — an estimated $417K sold.

Tounjian Advisory Partners first reported a position in GILD in Q1 2025 and held it in 2 quarters. The position peaked at $424K in Q1 2025. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Tounjian Advisory Partners reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Tounjian Advisory Partners sold 3,724 Gilead Sciences shares in Q3 2025, an estimated $417K.
  • Tounjian Advisory Partners first reported a position in Gilead Sciences in Q1 2025 and held it in 2 quarters.
  • Tounjian Advisory Partners's Gilead Sciences position peaked at $424K in Q1 2025.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Tounjian Advisory Partners's 13F filing for Q3 2025, filed 12 Nov 2025.